136 related articles for article (PubMed ID: 18630463)
1. Changes in tumour biological markers during primary systemic chemotherapy (PST).
Neubauer H; Gall C; Vogel U; Hornung R; Wallwiener D; Solomayer E; Fehm T
Anticancer Res; 2008; 28(3B):1797-804. PubMed ID: 18630463
[TBL] [Abstract][Full Text] [Related]
2. Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy.
Prisack HB; Karreman C; Modlich O; Audretsch W; Danae M; Rezai M; Bojar H
Anticancer Res; 2005; 25(6C):4615-21. PubMed ID: 16334152
[TBL] [Abstract][Full Text] [Related]
3. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
4. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer.
Wurster M; Ruoff A; Meisner C; Seeger H; Vogel U; Juhasz-Böss I; Solomayer E; Wallwiener D; Fehm T; Neubauer H
Oncol Rep; 2010 Sep; 24(3):653-9. PubMed ID: 20664970
[TBL] [Abstract][Full Text] [Related]
6. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.
Adams AL; Eltoum I; Krontiras H; Wang W; Chhieng DC
Breast J; 2008; 14(2):141-6. PubMed ID: 18248553
[TBL] [Abstract][Full Text] [Related]
7. [Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer].
Zhao J; Wu YL; Wang YD; Zhao GR; Wang J
Di Yi Jun Yi Da Xue Xue Bao; 2004 Dec; 24(12):1437-9. PubMed ID: 15604081
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
[TBL] [Abstract][Full Text] [Related]
9. [Effect of neoadjuvant chemotherapy on estrogen and progesterone receptors and P53 and CerbB-2 in breast cancer].
Bao G; Yang DQ; Zhou B; Liu P; Wang S; Cheng L
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(40):2843-5. PubMed ID: 18167290
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.
Miglietta L; Vanella P; Canobbio L; Parodi MA; Guglielmini P; Boccardo F
Anticancer Res; 2009 May; 29(5):1621-5. PubMed ID: 19443376
[TBL] [Abstract][Full Text] [Related]
11. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
Ivanov O; Chen F; Wiley EL; Keswani A; Diaz LK; Memmel HC; Rademaker A; Gradishar WJ; Morrow M; Khan SA; Cryns VL
Breast Cancer Res Treat; 2008 Oct; 111(3):411-7. PubMed ID: 17968656
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.
Faneyte IF; Schrama JG; Peterse JL; Remijnse PL; Rodenhuis S; van de Vijver MJ
Br J Cancer; 2003 Feb; 88(3):406-12. PubMed ID: 12569384
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
[TBL] [Abstract][Full Text] [Related]
14. Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer.
Warm M; Kates R; Mallmann P; Dick M; Nawroth F; Harbeck N; Paepke S; Thomas A
Anticancer Res; 2007; 27(2):1031-8. PubMed ID: 17465239
[TBL] [Abstract][Full Text] [Related]
15. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
17. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
18. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].
Kulka J; Tokés AM; Tóth AI; Szász AM; Farkas A; Borka K; Járay B; Székely E; Istók R; Lotz G; Madaras L; Korompay A; Harsányi L; László Z; Rusz Z; Molnár BA; Molnár IA; Kenessey I; Szentmártoni G; Székely B; Dank M
Magy Onkol; 2009 Dec; 53(4):335-43. PubMed ID: 20071305
[TBL] [Abstract][Full Text] [Related]
19. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours.
Bottini A; Berruti A; Bersiga A; Brunelli A; Brizzi MP; Marco BD; Cirillo F; Bolsi G; Bertoli G; Alquati P; Dogliotti L
Anticancer Res; 1996; 16(5B):3105-10. PubMed ID: 8920776
[TBL] [Abstract][Full Text] [Related]
20. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Allevi G; Bolsi G; Aguggini S; Brunelli A; Betri E; Generali D; Scaratti L; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2002 Jun; 8(6):1816-21. PubMed ID: 12060622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
